Current advances in targeted therapies for metastatic gastric cancer: improving patient care

Pedro Nazareth Aguiar1, Thiago Pimentel Muniz1, Raelson Rodrigues Miranda1

  • 1Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil.

Insights

Individual biomarkers are crucial for guiding targeted therapy in metastatic gastric cancer. Personalized biomarker evaluation is essential for improving patient survival and reducing costs, as tumors are heterogeneous.

Area of Science:

  • Oncology
  • Medical Genetics

Background:

  • Metastatic gastric cancer treatment relies on targeted therapies.
  • Current targeted therapy selection is limited by biomarker understanding.

Purpose of the Study:

  • To review advances in targeted therapies for metastatic gastric cancer.
  • To highlight the importance of personalized biomarkers in treatment selection.

Main Methods:

  • Literature review of current advances in targeted therapies.
  • Analysis of the role of biomarkers in patient selection.

Main Results:

  • HER2 overexpression is the only established predictive biomarker.
  • Gastric tumors exhibit significant heterogeneity.
  • Individual biomarkers are not fully elucidated but are key to effective therapy.

Conclusions:

  • Personalized biomarker evaluation is paramount for improving outcomes in advanced gastric cancer.
  • Understanding tumor heterogeneity is critical for novel therapeutic development.
  • Optimizing patient selection based on biomarkers can enhance survival and reduce healthcare costs.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
627
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
740